Marine Drug goes to Phase III trials to treat Lung Cancer

04/08/2016 - 2 minutes

PharmaMar is starting a new Phase III trial, with patients suffering from small cell lung cancer (SCLC). It’ll test the efficacy of its third candidate obtained from marine organisms (PM1183) as a SCLC treatment.

pharmamar small cell lung cancer treatmentPharmaMar is one of the hot Biotechs in Spain, which just saw its second drug finish Phase III trials with good results (and is already in trials for other indications, as we’ve seen at ASCO).

Now, PM1183 is under the spotlight. This cancer drug will be used in a second Phase III trial (after ovarian cancer). It’ll enrol 600 patients with small cell lung cancer (SCLC), for whom platinum-based treatments have failed before.

This type of lung cancer is less common than non-small cell lung cancer (which has very bad statistics) but has the worst prognosis for pulmonary cancers. Five years after diagnosis, only 5% to 10% of the patients are still alive.

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
Do you want to remove this advert? Become a member!
Do you want to remove this advert? Become a member!